Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postprandial lipemia, inflammation, and vascular function in diabetes modulated by SGLT2 inhibition
2016-001417-24Phase 4Active
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Postprandial leukocyte activation markers. Started Nov 2016; status: active.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-001417-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001417-24.